Association between cytogenetic and molecular data at study enrollment with response assessment after treatment
| Disease status at enrollment . | ELN 2017 . | Cytogenetic data . | Molecular mutations . | Best response on study . |
|---|---|---|---|---|
| ND | Adverse | Complex karyotype | TP53 | CR with MRD |
| Adverse | ASXL1 | CRi with MRD | ||
| Adverse | Complex, monosomal karyotype | Germline TP53 (Li Fraumeni) | CR without MRD | |
| Adverse | Del7q and del11q | CRi with MRD | ||
| Adverse | Monosomy 7 and rearrangement of MECOM | Persistent disease/refractory | ||
| Adverse | Complex karyotype | CR without MRD | ||
| R/R | Favorable | Biallelic CEBPA | CR without MRD | |
| Favorable | FLT3-TKD, NPM1 | Persistent disease/refractory | ||
| Favorable | Biallelic CEBPA | MLFS without MRD | ||
| Favorable | MECOM rearrangement at relapse | NPM1 at diagnosis | MLFS without MRD | |
| Intermediate | Germline DDX41 | Persistent disease/refractory | ||
| Intermediate | FLT3-TKD | CRi with MRD | ||
| Intermediate | Del7q31 at relapse | FLT3-TKD, ASXL1 at diagnosis | CRi without MRD | |
| Intermediate | CR without MRD | |||
| Adverse | ASXL1, BCOR | CRi without MRD | ||
| Adverse | ASXL1, RUNX1, SRSF2, STAG2 | MLFS without MRD | ||
| Adverse | Complex karyotype | TP53 | CRi with MRD | |
| Adverse | Del7q | SF3B1 | CR without MRD | |
| Adverse | ASXL1, RUNX1 | Death before evaluation | ||
| Adverse | Complex karyotype | TP53 | CRi with MRD |
| Disease status at enrollment . | ELN 2017 . | Cytogenetic data . | Molecular mutations . | Best response on study . |
|---|---|---|---|---|
| ND | Adverse | Complex karyotype | TP53 | CR with MRD |
| Adverse | ASXL1 | CRi with MRD | ||
| Adverse | Complex, monosomal karyotype | Germline TP53 (Li Fraumeni) | CR without MRD | |
| Adverse | Del7q and del11q | CRi with MRD | ||
| Adverse | Monosomy 7 and rearrangement of MECOM | Persistent disease/refractory | ||
| Adverse | Complex karyotype | CR without MRD | ||
| R/R | Favorable | Biallelic CEBPA | CR without MRD | |
| Favorable | FLT3-TKD, NPM1 | Persistent disease/refractory | ||
| Favorable | Biallelic CEBPA | MLFS without MRD | ||
| Favorable | MECOM rearrangement at relapse | NPM1 at diagnosis | MLFS without MRD | |
| Intermediate | Germline DDX41 | Persistent disease/refractory | ||
| Intermediate | FLT3-TKD | CRi with MRD | ||
| Intermediate | Del7q31 at relapse | FLT3-TKD, ASXL1 at diagnosis | CRi without MRD | |
| Intermediate | CR without MRD | |||
| Adverse | ASXL1, BCOR | CRi without MRD | ||
| Adverse | ASXL1, RUNX1, SRSF2, STAG2 | MLFS without MRD | ||
| Adverse | Complex karyotype | TP53 | CRi with MRD | |
| Adverse | Del7q | SF3B1 | CR without MRD | |
| Adverse | ASXL1, RUNX1 | Death before evaluation | ||
| Adverse | Complex karyotype | TP53 | CRi with MRD |
MLFS, morphologic leukemia-free state; TKD, tyrosine kinase domain.